Agha, R.A., Borrelli, M.R., Farwana, R., Koshy, K., Fowler, A. and Orgill, D.P. (2018) For the SCARE Group. The SCARE 2018 Statement: Updating Consensus Surgical CAse REport (SCARE) Guidelines. International Journal of Surgery, 60, 132-136.
https://doi.org/10.1016/j.ijsu.2018.10.028

has been cited by the following article:

• TITLE: Successful Management of Wound Dehiscence after Total Knee Arthroplasty by Topically Using Recombinant Basic Fibroblast Growth Factor

  AUTHORS: Jing Zhang, Zhiguo Lin

  KEYWORDS: Wound Dehiscence, Total Knee Arthroplasty, Recombinant Basic Fibroblast Growth Factor

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.9 No.6, June 16, 2020

  ABSTRACT: Wound complications are estimated to be affected in about 9% of TKA patients, which may increase the risk of deep periprosthetic infection and results in re-operation, joint fusion, or amputation. Here we have reported a female patient who suffered wound rupture due to early post-operation mobilization and weight-bearing. The wound dehiscence was successfully managed by applying recombinant basic fibroblast growth factor-2 and anti-infective treatment without removing prosthetic joint.